Results 11 to 20 of about 843,078 (353)

Cetuximab and biomarkers in non-small-cell lung carcinoma

Biologics: Targets & Therapy, 2012
Nitin Patil, Mohammed Abba, Heike AllgayerDepartment of Experimental Surgery, Medical Faculty Mannheim, University of Heidelberg and Molecular Oncology of Solid Tumors Unit, German Cancer Research Center (DKFZ), Heidelberg, GermanyAbstract: Cancer ...
Patil N, Abba M, Allgayer H
doaj   +5 more sources

Targeted therapy of non-small-cell lung carcinoma [PDF]

Therapeutic Advances in Respiratory Disease, 2012
The rapid expansion of novel technologies in cancer research over the past several years has led to a dramatically improved understanding of the molecular biology of lung cancer. As a consequence, novel targeted therapies are rapidly being developed.
Divya Tiwari, Seth A. Brodie, Johann C. Brandes   +2 more
doaj   +3 more sources

Long-term response to second-line afatinib treatment for advanced squamous cell carcinoma non-small cell lung cancer: a rare case report. [PDF]

J Int Med Res, 2020
The ErbB family is composed of four cell membrane receptors: ErbB-1 (epidermal growth factor receptor or human epidermal growth factor receptor [HER]1), ErbB-2 (HER2), ErbB-3 (HER3), and ErbB-4 (HER4).
Sun M, Guo Y, Wang X, Sun C, Shao J, Xu Y, Qiu S, Ma K.   +7 more
europepmc   +2 more sources

Cemiplimab for cutaneous squamous cell carcinoma, basal cell carcinoma, non-small cell lung cancer. [PDF]

Aust Prescr, 2022
europepmc   +2 more sources

Durvalumab for urothelial carcinoma, non-small cell lung cancer. [PDF]

Aust Prescr, 2019
europepmc   +2 more sources

Smad3 is essential for polarization of tumor-associated neutrophils in non-small cell lung carcinoma

Nature Communications, 2023
TGF-β stimulated tumor-associated neutrophils (TANs) can exert pro-tumoral functions. Here the authors show that Smad3 activation in TANs is associated with an N2-like polarization state and poor outcome in patients with non-small cell lung carcinoma and
J. Chung, P. Tang, Max Kam-Kwan Chan, V. Xue, Xiao-ru Huang, C. Ng, Dongmei Zhang, K. Leung, C. Wong, Tin-Lap Lee, E. Lam, D. Nikolic-Paterson, K. To, H. Lan, P. M. Tang   +14 more
semanticscholar   +1 more source

Non-small cell lung carcinoma (NSCLC): Implications on molecular pathology and advances in early diagnostics and therapeutics

Genes and Diseases, 2022
Continuous revision of the histologic and stage-wise classification of lung cancer by the World Health Organization (WHO) provides the foundation for therapeutic advances by promoting molecular targeted and immunotherapies and ensuring accurate diagnosis.
Hafiza Padinharayil, Jinsu Varghese, M. C. John, G. Rajanikant, Cornelia M. Wilson, Minnatallah Al-Yozbaki, K. Renu, S. Dewanjee, Rupa Sanyal, A. Dey, A. Mukherjee, Uddesh Ramesh Wanjari, A. V. Gopalakrishnan, Alex George   +13 more
semanticscholar   +1 more source

the Immunohistochemical Study of Stathmin-1 as A Prognostic factor In Non-small cell lung carcinoma

مجلة كلية الطب, 2023
Background Stathmin1 (also known as metablastin) is a major microtubule-depolymerizing protein that involved in cell cycle progression and cell motility.
Nadhema Bahaa Hussein Wetwet, Hadeel Abdulelah Karbel KERBEL, Ali Salih Baay Baay, Muhammed Whaeeb Salman Al-Obaidy   +3 more
doaj   +1 more source

Lung Cancer: A Literature Review

Jurnal Respirasi, 2023
Lung cancer is a cancer whose onset starts in the lungs where there is an abnormal cell growth that is very fast and uncontrolled. The abnormal cell growth is triggered by deoxyribonucleic acid (DNA) damage, including deletions in the DNA section ...
Yan Efrata Sembiring, Wiwin Is Effendi, Jeffrey Jeswant Dillon, Heroe Soebroto, Dhihintia Jiwangga Suta Winarno, Puruhito Puruhito, I Gusti Agung Made Adnyanya Putra, Abed Nego Okthara Sebayang, Sri Pramesthi Wisnu Bowo Negoro   +8 more
doaj   +1 more source

Dramatic response to pembrolizumab with chemotherapy followed by salvage surgery in a lung cancer patient

Thoracic Cancer, 2021
Immune checkpoint inhibitors with chemotherapy have been shown to exhibit remarkable efficacy for advanced non‐small‐cell lung carcinoma and are under investigation as an induction therapy.
Shunichi Saito, Gouji Toyokawa, Seiya Momosaki, Yuka Kozuma, Fumihiro Shoji, Koji Yamazaki, Sadanori Takeo   +6 more
doaj   +1 more source